In December 2015, BASAGLAR was the first insulin product approved through an abbreviated approval pathway under the Federal Food, Drug, and Cosmetic Act. The extensive clinical development program for BASAGLAR included pharmacokinetic and pharmacodynamic studies, as well as Phase III studies in people with type 1 and type 2 diabetes comparing the safety and efficacy of BASAGLAR to U.S.-and non-U.S.-approved Lantus.
| Website | http://www.basaglar.com |
| Revenue | $3 million |
| Employees | View employees |
| Address | PO Box 42638, Cincinnati, Ohio 45242, US |
| Industry | Manufacturing General, Manufacturing |
| Competitors | Lantus, Humulin, Forteo, NovoLog, Bantus Inc (view competitors) |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular Basaglar employee's phone or email?
Basaglar Questions
The Basaglar annual revenue was $3 million in 2026.
Basaglar is based in Cincinnati, Ohio.
The NAICS codes for Basaglar are [32541, 3254, 325, 32].
The SIC codes for Basaglar are [28, 283].
